Frieling U, Luger T A
Department of Dermatology, University of Münster, Germany.
Clin Exp Dermatol. 2002 Oct;27(7):562-70. doi: 10.1046/j.1365-2230.2002.01150.x.
In the past decade, there has been enormous progress in the understanding of the pathomechanisms of immune-mediated diseases, which has led to major advances in immunotherapeutic strategies. As a consequence, the armamentarium of specific and nonspecific immune-modulating and immunosuppressive drugs for the treatment of skin diseases has been widely extended. Among the nonspecific immunomodulators, mycophenolate mofetil and leflunomide show promising effects in a variety of autoimmune and inflammatory skin disorders. Both compounds inhibit a key enzyme in nucleotide biosynthesis, a step that is pivotal for the production of cytotoxic T cells and antibody formation. They do not act in the nucleus, which may explain their advantageous side-effect profile.
在过去十年中，我们对免疫介导疾病的发病机制的理解取得了巨大进展，这推动了免疫治疗策略的重大进步。因此，用于治疗皮肤病的特异性和非特异性免疫调节及免疫抑制药物的种类得到了广泛扩展。在非特异性免疫调节剂中，霉酚酸酯和来氟米特在多种自身免疫性和炎症性皮肤病中显示出有前景的疗效。这两种化合物都抑制核苷酸生物合成中的一种关键酶，这一步骤对于细胞毒性T细胞的产生和抗体形成至关重要。它们不在细胞核中起作用，这可能解释了它们有利的副作用特征。
